{"id":"NCT00664859","sponsor":"Veloxis Pharmaceuticals","briefTitle":"12-Month, Open-Label, Extension Study of LCP-AtorFen in Dyslipidemia","officialTitle":"A 12-Month, Open-Label, Extension Study of the Safety and Efficacy of LCP-AtorFen in Subjects With Dyslipidemia","status":"COMPLETED","phase":"PHASE2","dates":{"start":"2007-10","primaryCompletion":"2009-02","completion":"2009-02","firstPosted":"2008-04-23","resultsPosted":"2020-03-24","lastUpdate":"2020-03-24"},"enrollment":140,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Dyslipidemia"],"interventions":[{"type":"DRUG","name":"LCP-AtorFen","otherNames":["atorvastatin and fenofibrate combination therapy"]}],"arms":[{"label":"Single","type":"EXPERIMENTAL"}],"summary":"The current study is designed to test the long-term (12-month) safety and efficacy of LCP-AtorFen, a combination of atorvastatin and fenofibrate, in patients with dyslipidemia","primaryOutcome":{"measure":"Change in Non-HDL Cholesterol, HDL Cholesterol, TG Levels From Baseline to End of Treatment","timeFrame":"52 weeks from DB baseline and 40 weeks from OL baseline","effectByArm":[{"arm":"LCP-AtorFen 40/100mg","deltaMin":-48.2,"sd":13.58},{"arm":"Atorvastatin 40 mg","deltaMin":-43.6,"sd":18.18},{"arm":"Fenofibrate 145 mg","deltaMin":-42,"sd":20.49}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":1,"countries":["United States"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":3,"n":51},"commonTop":["Nasopharyngitis","Upper respiratory tract infection","Diarrhoea","Blood glucose increased","Muscle spasms"]}}